Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453749 | 1.00 | ACHE (0.56) | ACHEFAAHMGLLMEN1KMT2A | |
| SCHEMBL1581891 | 0.86 | GRIN2D (0.50) | ACHEGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL16825166 | 0.86 | MEN1 (0.54) | MEN1KMT2A | |
| SCHEMBL1581417 | 0.84 | CYP1A2 (0.52) | ACHEGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2636547 | 0.83 | MEN1 (0.68) | FAAHMGLLMEN1KMT2A | |
| SCHEMBL3640283 | 0.81 | KDM4E (0.54) | ACHE | |
| SCHEMBL5749445 | 0.81 | MEN1 (0.57) | FAAHMGLLMEN1KMT2A | |
| SCHEMBL3347967 | 0.80 | FAAH (0.76) | FAAHMGLLMEN1KMT2A | |
| SCHEMBL7231605 | 0.80 | ACHE (0.70) | ACHEMGLLMEN1KMT2ACHRM2 | |
| SCHEMBL8625212 | 0.79 | CYP1A2 (0.52) | ACHEKMT2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101686979-A | The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces | JANSSEN PHARMACEUTICA NV | 2010-03-31 | — | — | CN | claimed |
| EP-2164493-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-03-24 | — | — | EP | claimed |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-05 | — | — | US | claimed |
| WO-2008153752-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | claimed |
| EP-1720872-B1 | ARYL AND HETEROARYL-PIPERIDINECARBOXYLATE DERIVATIVES, THE PREPARATION AND THE USE THEREOF IN THE FORM OF FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2011-04-20 | — | — | EP | disclosed |
| CN-101686979-A | The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces | JANSSEN PHARMACEUTICA NV | 2010-03-31 | — | — | CN | disclosed |
| EP-2164493-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-03-24 | — | — | EP | disclosed |
| CN-100549012-C | Aryl-and heteroaryl-piperidinecarboxylic acid derivatives, their preparation and use as FAAH enzyme inhibitors | SANOFI AVENTIS (FR) | 2009-10-14 | — | — | CN | disclosed |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008153752-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
| CN-1922177-A | Aryl-and heteroaryl-piperidinecarboxylic acid derivatives, their preparation and use as FAAH enzyme inhibitors | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | CN | disclosed |
| EP-1720872-A1 | ARYL AND HETEROARYL-PIPERIDINECARBOXYLATE DERIVATIVES, THE PREPARATION AND THE USE THEREOF IN THE FORM OF FAAH ENZYME INHIBITORS | Sanofi-Aventis (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005090347-A1 | ARYL AND HETEROARYL-PIPERIDINECARBOXYLATE DERIVATIVES, THE PREPARATION AND THE USE THEREOF IN THE FORM OF FAAH ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | ACHE 500/4885FAAH 1/4885MGLL 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.